연구용
제품 번호: S2504
화학 구조
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| E6SM cell lines | Function assay | Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines, EC50=0.005 μM | ||||
| MDCK cells | Function assay | 3 days | Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis, EC50=0.094 μM | |||
| mouse L1210 cells | Function assay | 20-60 mins | Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM | |||
| human CEM cells | Function assay | 20-60 mins | Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM | |||
| BHK21 cell line | Function assay | Inhibition of West Nile virus VLP replicon in BHK21 cell line, EC50=1.1 μM | ||||
| HeLa cell | Function assay | Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines, EC50=1.5 μM | ||||
| MDCK cells | Function assay | 36 h | Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs, IC50=1.9 μM | |||
| MDBK cells | Function assay | 2 days | Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay, EC50=4.6 μM | |||
| african green monkey Vero cells | Function assay | 5 days | Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay, EC50=7 μM | |||
| HEL cells | Function assay | 2-3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=10 μM | |||
| HEK293 cells | Function assay | 24 h | Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay, EC50=15 μM | |||
| human BE(2)-C cells | Function assay | 18-20 h | Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay, IC50=16 μM | |||
| human HuH7-J20 cells | Function assay | Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs, EC50=30.4 μM | ||||
| human MT4 cells | Cytotoxic assay | 96 h | Cytotoxicity against human MT4 cells after 96 hrs by MTT assay, CC50=31 μM | |||
| human HuH7 cells | Cytotoxic assay | 3 days | Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay, CC50=32 μM | |||
| human KB cells | Function assay | 72 h | Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control | |||
| human KB cells | Function assay | 1-1000 μg/ml | 72 h | Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 244.20864 | 화학식 | C8H12N4O5 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 36791-04-5 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NSC-163039, RTCA, Tribavirin | Smiles | C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N | ||
|
In vitro |
DMSO
: 49 mg/mL
(200.64 mM)
Water : 49 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| 시험관 내(In vitro) |
Ribavirin (ICN-1229) significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although it has little effect on levels of HCV replication. This compound increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. It enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. It reduces infectious poliovirus production to as little as 0. 00001% in cell culture. Its antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. This compound markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). It inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. It is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. It is thought to induce a switch in T-helper cell phenotype from type 2 to type 1.
|
참조 |
|
|---|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p53 / p-p53 / p21 / Mdm2 EZH2 / p-ERK / ERK / p-eIF4E / eIF4E / p21 Cyclin D1 p-AKT / AKT / pBP1 / BP1 |
|
22962590 |
| Growth inhibition assay | Cell number |
|
21415224 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT05940545 | Recruiting | CCHF |
Liverpool School of Tropical Medicine |
July 12 2023 | Phase 1|Phase 2 |
| NCT04283513 | Not yet recruiting | Hemorrhagic Fever |
U.S. Army Medical Research and Development Command |
October 31 2022 | Phase 2 |
| NCT04335123 | Completed | COVID-19 |
University of Kansas Medical Center |
April 4 2020 | Phase 1 |
| NCT04285034 | Completed | Lassa Fever |
University of Oxford |
November 26 2019 | -- |
| NCT03889106 | Terminated | Lassa Fever |
University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England |
March 1 2019 | -- |
| NCT03585725 | Terminated | Follicular Lymphoma|Mantle Cell Lymphoma |
Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center |
September 26 2018 | Early Phase 1 |